Faculty

Institution

Unit

Venue

Monica Loghin

The University of Texas MD Anderson Cancer Center

Affiliations

Center Of Brain Tumour

The University of Texas MD Anderson Cancer Center

NoneMonica Loghin is currently serving as a Center Of Brain Tumour faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Monica Loghin

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

oncology neuro-oncology brain tumor research neurology radiation oncology gliomas cancer treatment medicine cancer research cancer care radiation therapy pharmacology pharmacotherapy surgical oncology clinical radiation oncology neuroradiology cancer management neurosurgery clinical research cancer immunotherapy neuropathology medicinal research vascular biology clinical trials clinical neurology brain lesion cancer discovery cancer biology neurological disorders spinal oncology drug trials cancer patients cellular therapy disease progression immune checkpoint inhibitors recurrent glioblastoma gut microbes spinal cord spinal cord medicine leukemia stem cell research neurologic intensive care spinal tumors drug safety clinical neuroscience clinical evidence phase iii phase ii study dose-dense temozolomide postradiation adjuvant therapy window-of-opportunity clinical trial facial pain dimensioning and tolerancing intermittently connected device in vivo systems treatment and prevention thermally activated delayed fluorescence brachytherapy immunologic mechanisms immunotoxicology molecular immunology cluster headache neuroinflammation randomized controlled trials clinical endpoint gut-organ axis prognostic biomarkers radiation necrosis bevacizumab therapy double-blind placebo-controlled trial placebo-controlled clinical trial immune-suppressive macrophages tumor subtype leptomeningeal disease factorial study low dose bevacizumab

Notable Scholarly Works

Notable Federal Grants

Collaborators

Combination of Metronomic Oral Pazopanib and Topotecan for Recurrent Glioblastoma With and Without Previous Bevacizumab: Results From a Phase 2 Clinical Trial. Neuro-Oncology Advances (2026)

metronomic therapyoncologyradiation oncologyprevious bevacizumabneuro-oncologycancer treatmentbrain tumor researchphase 2gliomasneurologyjama oncologymetronomic oral pazopanib

Extra-Central Nervous System Metastasis From High-Grade Glioma: A Single-Institution Experience. Journal of Neuro-Oncology (2025)

Christina Abi FarajIan E. McCutcheonMaria A. GubbiottiSubha PerniMaria K. Gule-MonroeKadir AkdemirVictoria E. ClarkEvan D. BanderMonica E. LoghinSujit S. PrabhuFrederick F. LangJeffrey S. Weinberg

metastasisneuro-oncologysingle-institution experiencebrain tumor researchgliomasneurologyhigh-grade glioma

Improved Overall Survival in an Anti-Pd-L1 Treated Cohort of Newly Diagnosed Glioblastoma Patients is Associated With Distinct Immune, Mutation, and Gut Microbiome Features: A Single Arm Prospective Phase I/II Trial. Nature Communications (2025)

cancer immunotherapymolecular diagnosticsmedicinegut-organ axisoncologyoverall survivaldistinct immuneneuro-oncologyimmunotherapyimmune checkpoint inhibitorsmicrobiome featuresimmunologybrain tumor researchgut microbesgliomasprognostic biomarkerscancer discovery

Prospective Phase II Clinical Trial of Molecular Glioblastoma (Historical Grade 2 and 3 Idh Wildtype Gliomas) Preliminary Novel Exploratory Analyses. Journal of Neuro-Oncology (2025)

brain pathologymolecular cancerneuro-oncologybrain lesioncancer treatmentbrain tumor researchgliomasneurology

Accelerated Tumor Progression After Covid-19 Infection in Patients With Glioblastoma: A Retrospective Case–Control Study. Neuro-Oncology Practice (2024)

Timothy A GregoryStephanie R KnightAshley E AaroeKaitlin N HighsmithZachary C JanatpourBarbara J O’BrienNazanin K MajdMonica E LoghinChirag B PatelShiao-Pei WeathersVinay K PuduvalliCarlos Kamiya-Matsuoka

gliomasgeneral virologyurologyoncologycancer carecancer treatmentbrain tumor researchdisease progressioninfectious diseasestumor progressionneuro-oncologysars-cov-2vascular biologyradiologyretrospective case-control studysurgical oncologycovid-19retrospective cohort studiescancer managementviral oncology

Author Correction: Distinct Molecular and Immune Hallmarks of Inflammatory Arthritis Induced by Immune Checkpoint Inhibitors for Cancer Therapy. Nature Communications (2024)

Sang T. KimYanshuo ChuMercy MisoiMaria E. Suarez-AlmazorJean H. TayarHuifang LuMaryam BuniJordan KramerEmma RodriguezZulekha HussainSattva S. NeelapuJennifer WangAmishi Y. ShahNizar M. TannirMatthew T. CampbellDon L. GibbonsTina CasconeCharles LuGeorge R. BlumenscheinMehmet AltanBora LimVincente ValeroMonica E. LoghinJanet TuShannon N. WestinAung NaingGuillermo Garcia-ManeroNoha Abdel-WahabHussein A. TawbiPatrick HwuIsabella C. Glitza OlivaMichael A. DaviesSapna P. PatelJun ZouAndrew FutrealAdi DiabLinghua WangRoza Nurieva

chronic inflammationcancer immunotherapyinflammatory arthritismedicinecancer therapypharmacologyrheumatologyoncologycancer researchauthor correctionimmune hallmarksimmunotherapycancer careclinical immunologycancer treatmenttherapeutic efficacyimmunologyanti-inflammatorymedicinal researchclinical rheumatologyexperimental medicinepharmacotherapy

Early Outcomes From Proton Craniospinal Irradiation for Leptomeningeal Metastasis From Solid Tumors. Advances in Radiation Oncology (2024)

metastasissurgical oncologyradiation therapyoncologyradiation oncologysurgeryproton craniospinal irradiationneurosurgeryneuro-oncologyclinical radiation oncologyearly outcomes

Proton Craniospinal Irradiation for Treatment of Leptomeningeal Metastasis in Patients With Solid Malignancy: The MD Anderson Cancer Center Experience (S27.006). Neurology (2024)

metastasissurgical oncologyradiation therapysolid malignancyoncologyradiation oncologyproton craniospinal irradiationneurosurgeryleptomeningeal metastasisradiationclinical radiation oncologyradiology

Toxicity in the Era of Immune Checkpoint Inhibitor Therapy. Frontiers in Immunology (2024)

Synat KeamNaimah TurnerFernanda G. KugeratskiRene RicoJocelynn Colunga-MinuttiRayansh PoojarySayan AlekseevAnisha B. PatelYuanteng Jeff LiAjay SheshadriMonica E. LoghinKarin WoodmanAshley E. AaroeSarah HamidiPriyanka Chandrasekhar IyerNicolas L. PalaskasYinghong WangRoza Nurieva

cancer immunotherapyimmunotoxicologyimmunologic mechanismsmolecular immunologyimmune checkpoint inhibitorsimmunotherapyimmunologypharmacologytherapeutic targetsmedicinal research

Ctim-23. Safety Run-in Results of a Phase I/II Study to Evaluate Atezolizumab in Combination With Cabozantinib in Patients With Recurrent Glioblastoma. Neuro-Oncology (2023)

Shiao-Pei WeathersCarlos Kamiya-MatsuokaNazanin MajdAlda AshuChantell ThompsonEvguenia GachimovaAshley AaroeChirag PatelMonica LoghinBarbara O'BrienW K Alfred YungVinay PuduvalliJohn de Groot

cancer immunotherapygliomasurologyoncologycancer researchcancer careclinical neurologycancer treatmentbrain tumor researchcancer discoverydisease progressiondrug safetyrecurrent glioblastomaneuro-oncologyradiologymedicinal researchdrug trialsanesthesiologypharmacotherapy

1
2
3
4
5
9
10 / page

Monica Loghin

The University of Texas MD Anderson Cancer Center

Affiliations

Center Of Brain Tumour

The University of Texas MD Anderson Cancer Center

NoneMonica Loghin is currently serving as a Center Of Brain Tumour faculty at The University of Texas Md Anderson Cancer Center.

Honors

Create free account to unlock more features

Experiences

Create free account to unlock more features

Education

Create free account to unlock more features

Monica Loghin

The University of Texas MD Anderson Cancer Center

You can click a keyword to filter the displayed items

Notable Scholarly Works

Notable Federal Grants

Collaborators

Combination of Metronomic Oral Pazopanib and Topotecan for Recurrent Glioblastoma With and Without Previous Bevacizumab: Results From a Phase 2 Clinical Trial. Neuro-Oncology Advances (2026)

metronomic therapyoncologyradiation oncologyprevious bevacizumabneuro-oncologycancer treatmentbrain tumor researchphase 2gliomasneurologyjama oncologymetronomic oral pazopanib

Extra-Central Nervous System Metastasis From High-Grade Glioma: A Single-Institution Experience. Journal of Neuro-Oncology (2025)

Christina Abi FarajIan E. McCutcheonMaria A. GubbiottiSubha PerniMaria K. Gule-MonroeKadir AkdemirVictoria E. ClarkEvan D. BanderMonica E. LoghinSujit S. PrabhuFrederick F. LangJeffrey S. Weinberg

metastasisneuro-oncologysingle-institution experiencebrain tumor researchgliomasneurologyhigh-grade glioma

Prospective Phase II Clinical Trial of Molecular Glioblastoma (Historical Grade 2 and 3 Idh Wildtype Gliomas) Preliminary Novel Exploratory Analyses. Journal of Neuro-Oncology (2025)

brain pathologymolecular cancerneuro-oncologybrain lesioncancer treatmentbrain tumor researchgliomasneurology

Accelerated Tumor Progression After Covid-19 Infection in Patients With Glioblastoma: A Retrospective Case–Control Study. Neuro-Oncology Practice (2024)

Author Correction: Distinct Molecular and Immune Hallmarks of Inflammatory Arthritis Induced by Immune Checkpoint Inhibitors for Cancer Therapy. Nature Communications (2024)

Early Outcomes From Proton Craniospinal Irradiation for Leptomeningeal Metastasis From Solid Tumors. Advances in Radiation Oncology (2024)

metastasissurgical oncologyradiation therapyoncologyradiation oncologysurgeryproton craniospinal irradiationneurosurgeryneuro-oncologyclinical radiation oncologyearly outcomes

Proton Craniospinal Irradiation for Treatment of Leptomeningeal Metastasis in Patients With Solid Malignancy: The MD Anderson Cancer Center Experience (S27.006). Neurology (2024)

metastasissurgical oncologyradiation therapysolid malignancyoncologyradiation oncologyproton craniospinal irradiationneurosurgeryleptomeningeal metastasisradiationclinical radiation oncologyradiology

Toxicity in the Era of Immune Checkpoint Inhibitor Therapy. Frontiers in Immunology (2024)

cancer immunotherapyimmunotoxicologyimmunologic mechanismsmolecular immunologyimmune checkpoint inhibitorsimmunotherapyimmunologypharmacologytherapeutic targetsmedicinal research

Ctim-23. Safety Run-in Results of a Phase I/II Study to Evaluate Atezolizumab in Combination With Cabozantinib in Patients With Recurrent Glioblastoma. Neuro-Oncology (2023)

Shiao-Pei WeathersCarlos Kamiya-MatsuokaNazanin MajdAlda AshuChantell ThompsonEvguenia GachimovaAshley AaroeChirag PatelMonica LoghinBarbara O'BrienW K Alfred YungVinay PuduvalliJohn de Groot

1
2
3
4
5
9
10 / page